Running summarizing tools on a new article
Check the paper below, then start its synthesis.
SARS-CoV-2 Seroconversion and Viral Clearance in Patients Hospitalized With COVID-19: Viral Load Predicts Antibody Response
Mar Masiá (Universitat de Miguel Hernández d'Elx, Hospital General Universitario de Elche), Guillermo Telenti (Hospital General Universitario de Elche), Marta Fernández‐González (Hospital General Universitario de Elche), José Alberto García (Universitat de Miguel Hernández d'Elx), Vanesa Agulló (Hospital General Universitario de Elche), Sergio Padilla (Hospital General Universitario de Elche), Javier García‐Abellán (Hospital General Universitario de Elche), Lucía Guillén (Hospital General Universitario de Elche), Paula Mascarell (Hospital General Universitario de Elche), José C Asenjo (Hospital General Universitario de Elche), Félix Gutiérrez (Universitat de Miguel Hernández d'Elx, Hospital General Universitario de Elche)
Abstract: Abstract Background The interdependencies of viral replication and the host immune response in patients with coronavirus disease 2019 (COVID-19) remain to be defined. We investigated the viral determinants of antibody response, the predictors of nonseroconversion, and the role of antibodies on viral dynamics. Methods This was a prospective study in patients hospitalized with COVID-19 that was microbiologically confirmed by real-time polymerase chain reaction (RT-PCR). Serial nasopharyngeal and oropharyngeal swabs and plasma samples were obtained for measuring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA and antibodies (total and S-IgG/N-IgG), respectively. Results Of 132 patients included, 99 (75%) showed positive antibody titers after a median (Q1–Q3) of 11 (8–14) days. The median (Q1–Q3) follow-up was 74.5 (63.0–87.0) days. In an adjusted linear regression model, time to seropositivity was inversely associated with peak log SARS-CoV-2 viral load (P = .009) and positively with time to viral clearance (P = .004). Adjusted predictors of S-IgG levels were time to viral clearance (P < .001), bilateral lung infiltrates on admission (P = .011), and the time-dependent SARS-CoV-2 RNA (P < .001) and SARS-CoV-2 RNA area under the curve (P = .001). Thirty-three (25%) patients showed undetectable antibody titers. Patients who did not seroconvert had higher cycle threshold values of RT-PCR (38.0 vs 28.0; P < .001), had shorter time to viral clearance (3.0 vs 41.0; P < .001), and were more likely to have SARS-CoV-2 only detected on fecal samples (P < .001). Nonseroconvertors had also lower levels of blood inflammatory biomarkers on admission and lower disease severity. Conclusions Viral replication determines the magnitude of antibody response to SARS-CoV-2, which, in turn, contributes to viral clearance. COVID-19 patients who do not seroconvert exhibit a differential virological and clinical profile.